Evidence map›Paper›PMID 36576430›Full record

Trial reportThe oncologist2023

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.

Luis Meza, David F McDermott, Bernard Escudier, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael B Atkins, Vijay Kasturi, Sumanta K Pal, Brian Rini

Open access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 3 countries.

Luis MezaDepartment of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID 0000-0002-0235-297X
David F McDermottDepartment of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, USA.
Bernard EscudierDepartment of Medical Oncology, Gustave Roussy, Villejuif, France.
Thomas E HutsonDepartment of Hematology and Medical Oncology, Texas A&M University College of Medicine, Bryan, TX, USA.
Camillo PortaDepartment of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro and Policlinico Consorziale di Bari, Bari, Italy.
Elena VerzoniDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Michael B AtkinsDepartment of Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Vijay KasturiClinical Development and Medical Affairs, Aveo Oncology, Boston, MA, USA.
Sumanta K PalDepartment of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Brian RiniDivision of Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
City of Hope · USAVEO Oncology (United States) · USBeth Israel Deaconess Medical Center · USFondazione IRCCS Istituto Nazionale dei Tumori · ITGeorgetown University Medical Center · USInstitut Gustave Roussy · FRTexas A&M Health Science Center · USUniversity of Bari Aldo Moro · ITVanderbilt University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we characterize the clinical efficacy of tivozanib in patients with mRCC previously treated with axitinib.

methodsWe identified patients from the intention to treat (ITT) population, in the TIVO-3 trial, who received treatment with axitinib before enrolment in the study and evaluated PFS, response rate (RR), and safety.

resultsOut of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib.

conclusionsTivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib.

Indexed as

Antineoplastic AgentsCarcinoma, Renal CellKidney NeoplasmsAxitinibHumansPhenylurea CompoundsQuinolinesSorafenibAntineoplastic AgentsAxitinibPhenylurea CompoundsQuinolinesSorafenibtivozanibaxitinibmetastatic renal cell carcinomasorafenibtivozanibvascular endothelial growth factor inhibitor

Identifiers

PMID36576430
PMCPMC10020797
OpenAlexW4313205689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.